[1] SHIN J S, HONG A, SOLOMON M J, et al. The role of telomeres and telomerase in the pathology of human cancer and aging[J]. Pathology,2006,38(2):103-113.
[2] HARTWIG F P, BERTOLDI D, LARANGEIRA M, et al. Upregulating telomerase and tumor suppressors:Focusing on antiaging interventions at the population level[J]. Aging Dis,2014,5(1):17-26.
[3] MITTELDORF J J. Telomere biology:Cancer firewall or aging clock?[J].Biochemistry (Mosc),2013,78(9):1054-1060.
[4] PANERO J, STELLA F, SCHUTZ N, et al. Differential expression of non-shelterin genes associated with high telomerase levels and telomere shortening in plasma cell disorders[J]. PLoS One,2015,10(9):e0137972.
[5] VAN STEENSEL B, SMOGORZEWSKA A, DE LANGE T. TRF2 protects human telomeres from end-to-end fusions[J]. Cell, 1998,92(3):401-413.
[6] DE LANGE T. Shelterin:the protein complex that shapes and safeguards human telomeres[J]. Genes Dev,2005,19(18):2100-2110.
[7] MENGUAL GOMEZ D L, ARMANDO R G, FARINA H G, et al. Telomerase and telomere:their structure and dynamics in health and disease[J]. Medicina (B Aires), 2014,74(1):69-76.
[8] PALM W, DE LANGE T. How shelterin protects mammalian telomeres[J]. Annu Rev Genet,2008,42(0):301-334.
[9] CHAPMAN L, FAIRALL L, RHODES D. How the human telomeric proteins TRF1 and TRF2 recognize telomeric DNA:a view from high-resolution crystal structures[J]. EMBO Rep,2005, 6(1):39-45.
[10] OKAMOTO K,BARTOCCI C,OUZOUNOV I,et al. A two-step mechanism for TRF2-mediated chromosome end protection[J]. Nature,2013,494(7438):502-505.
[11] VAN STEENSEL B, DE LANGE T. Control of telomere length by the human telomeric protein TRF1[J]. Nature, 1997, 385(6618):740-743.
[12] SFEIR A, KOSIYATRAKUL S T, HOCKEMEYER D, et al. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication[J]. Cell,2009,138(1):90-103.
[13] CHENG Q, CHEN J. Mechanism of p53 stabilization by ATM after DNA damage[J]. Cell Cycle,2010,9(3):472-478.
[14] SAREK G, VANNIER J B, PANIER S, et al. TRF2 recruits RTEL1 to telomeres in S phase to promote t-loop unwinding[J]. Mol Cell,2015,57(4):622-635.
[15] WAN B, YIN J, HORVATH K, et al. SLX4 assembles a telomere maintenance toolkit by bridging multiple endonucleases with telomeres[J]. Cell Rep,2013,4(5):861-869.
[16] LI J S Z, FUSTE J M, SIMAVORIAN T, et al. TZAP:a telomere-associated protein involved in telomere length control[J]. Science,2017,355(6325):638-641.
[17] DIEHL M C, IDOWU M O, KIMMELSHUE K N, et al. Elevated TRF2 in advanced breast cancers with short telomeres[J]. Breast Cancer Res Treat,2011,127(3):623-630.
[18] PAL D, SHARMA U, SINGH S K, et al. Over-expression of telomere binding factors (TRF1&TRF2) in renal cell carcinoma and their inhibition by using SiRNA induce apoptosis, reduce cell proliferation and migration in vitro[J]. PloS One, 2015, 10(3):e0115651.
[19] RICE C, SHASTRULA P K, KOSSENKOV A V, et al.Structural and functional analysis of the human POT1-TPP1 telomeric complex[J]. Nat Commu,2017,10(8):14928.
[20] YE J Z S, HOCKEMEYER D, KRUTCHINSKY A N, et al. POT1-interacting protein PIP1:a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex[J]. Genes Dev, 2004, 18(14):1649-1654.
[21] ZHONG F L,BATISTA L F Z,FREUND A,et al. TPP1 OBfold domain controls telomere maintenance by recruiting telomerase to chromosome ends[J]. Cell,2012,150(3):481-494.
[22] CHANG S. Cancer chromosomes going to POT1[J]. Nat Genet, 2013,45(5):473-475.
[23] CHEN C, GU P, WU J, et al. Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in human cancer[J]. Nat Commu,2017,10(8):14929.
[24] QIANG W, WU Q, ZHOU F, et al. Suppression of telomerebinding protein TPP1 resulted in telomere dysfunction and enhanced radiation sensitivity in telomerase-negative osteosarcoma cell line[J]. Biochem Biophys Res Commun, 2014,445(2):363-368.
[25] AHMAD T, SUNDAR I K, TORMOS A M, et al. Shelterin telomere protection protein 1 reduction causes telomere attrition and cellular senescence via sirtuin 1 deacetylase in chronic obstructive pulmonary disease[J]. Am J Respir Cell Mol Biol, 2017,56(1):38-49.
[26] FRESCAS D, DE LANGE T. Binding of TPP1 protein to TIN2 protein is required for POT1a, b protein-mediated telomere protection[J]. J Biol Chem,2014,289(35):24180-24187.
[27] CHEN L Y, ZHANG Y, ZHANG Q, et al. Mitochondrial localization of telomeric protein TIN2 links telomere regulation to metabolic control[J]. Mol Cell,2012,47(6):839-850.
[28] SULLIVAN L B, SANTOS J H, CHANDEL N S. Mitochondria and telomeres:the promiscuous roles of TIN2[J]. Mol Cell, 2012,47(6):823-824.
[29] RAI R, CHEN Y, LEI M, et al. TRF2-RAP1 is required to protect telomeres from engaging in homologous recombinationmediated deletions and fusions[J]. Nat Commu, 2016, 4(7):10881.
[30] MARTINEZ P, THANASOULA M, CARLOS A R, et al. Mammalian RAP1 controls telomere function and gene expression through binding to telomeric and extra-telomeric sites[J]. Nat Cell Biol,2010,12(8):768.
[31] KABIR S, SFEIR A, DE LANGE T. Taking apart Rap1:an adaptor protein with telomeric and non-telomeric functions[J]. Cell Cycle,2010,9(20):4061-4067.
[32] BENARROCH-POPIVKER D,PISANO S,MENDEZ-BERMUDEZ A,et al. TRF2-mediated control of telomere DNA topology as a mechanism for chromosome-end protection[J]. Mol Cell,2016,61(2):274-286.
[33] PAL D, SINGH S K, KAKKAR N, et al. Expression of telomere binding proteins (RAP1 and POT1) in renal cell carcinoma and their correlation with clinicopathological parameters[J]. Indian J Clin Biochem,2017,32(3):301-305.
[34] MACIEJOWSKI J, DE LANGE T. Telomeres in cancer:tumour suppression and genome instability[J]. Nat Rev Mol Cell Biol, 2017,18(3):175-186. |
